2015 Fiscal Year Final Research Report
Molecular mechanism of progression to castration resistant prostate cancer and its application for tailor made treatment
| Project/Area Number |
25462503
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Toho University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 前立腺癌 / 去勢抵抗性前立腺癌 / ERG / 予後予測モデル / PET / ドセタキセル / 酢酸アビラテロン / アンチアンドロゲン |
|---|
| Outline of Final Research Achievements |
To investigate the association of ERG expression, one of the most important molecular mechanism of progression to castration resistant prostate cancer (CRPC), with other molecular abnormalities, we examined specimens from radical prostatectomy, prostate biopsy, trans-urethral resection and autopsy. We examined the potential association of ERG expression and other gene abnormalities and clinical factors and found that ERG expression plays an important role of progression of CRPC. Especially, ERG expression was strongly related to PTEN expression.
Also, we examined prognostic factors for efficacy of each CRPC drugs and made statistical prognostic models (nomograms).
We have developed novel PET diagnostic drug reconizing amino acid tranportor and we attended the first global advanced prostate cancer conference held at St. Gallen, Switzland as a consensus panel member and debated about these new findings and other future CRPC treatment.
|
| Free Research Field |
泌尿器科学
|
